ESMO Breast 2021 | Brain metastases in HER2+ breast cancer
Volkar Mueller, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the incidence of brain metastases in patients with breast cancer, as presented at the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021. In this video, Dr Mueller highlights new therapeutic approaches in patients with HER2+ breast cancer with brain metastases such as tucatinib, neratinib and T-DM1, as well as the challenges associated with treating this patient population. This interview took place at the virtual ESMO Breast Cancer Congress 2021.
Disclosures
Volkar Mueller, MD, has received speaker honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva and Seattle Genetics; has received consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro and Nektar; has received institutional research support from Novartis, Roche, Seattle Genetics and Genentech; and has received travel grants from Roche, Pfizer and Daiichi Sankyo.
